Clinical Trials

Trials at Arkansas Urology

A clinical trial is a research study that finds new ways to treat a disease. The Arkansas Urology Research Center (AURC)  participates in several clinical research trials to offer therapies to our patients that are not yet available at other local practices or clinics in Arkansas. These clinical trials are available to men and women of all ages.

You’ll find a few studies that we are actively enrolling our patients in listed below. We have additional studies not listed. Please contac the AURC at 501-219-8900 x 9039 if you are interested in learning more about these studies and/or other research opportunities.

Janssen LogoHigh Risk Hormone Sensitive Prostate Cancer

CLICK HERE TO LEARN MORE ABOUT TRIAL

PRIMORDIUM-A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET, with an Observational Cohort

Janssen LogoMetastatic Castration-Sensitive Prostate Cancer

CLICK HERE TO LEARN MORE ABOUT TRIAL

LIBERTAS-A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

GREGOR DIAGNOSTICS  *Semen Collection at the Time of Prostate Biopsy

CLICK HERE TO LEARN ABOUT SEMEN COLLECTION FOR PROSTATE CANCER DIAGNOSTICS

Blood Collection at the Time of Prostate Biopsy

The purpose of this research is to see if a new, experimental blood test might help men with prostate cancer who are on active surveillance need fewer prostate needle biopsies.

A blood sample is collected in Little Rock at the lab or at the surgery center prior to your biopsy.

Myovant Sciences

Observational Study of Patients of Being Treated ORGOVYX

CLICK HERE TO LEARN MORE ABOUT TRIAL

OPTYX-A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

 

Janssen Logo

High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

CLICK HERE TO LEARN MORE ABOUT TRIAL

SUNRISE 3-Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Janssen Logo

Muscle Invasive Bladder Cancer

CLICK HERE TO LEARN MORE ABOUT TRIAL

SUNRISE-4-Janssen is conducting a Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy.

 

Non-Muscle Invasive Bladder Cancer

CLICK HERE TO LEARN MORE ABOUT TRIAL

AURA-A Phase 1, open-label trial of belzupacap sarotalocan (AU-011) to determine the feasibility and safety of intramural injection with or without intratumoral injection in subjects with non-muscle invasive bladder cancer (NMIBC)

High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

CLICK HERE TO LEARN MORE ABOUT TRIAL

UR001-A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (zalifrelimab) Administered Intravesically as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

CLICK HERE TO LEARN MORE ABOUT TRIAL

PATAPSCO-This is an open-label, single-arm, multi-center, Phase IIIb US study exploring the combination of durvalumab and BCG (induction and maintenance) in participants with high-risk NMIBC

PEAK-Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

Optilume Info and Video

 

created by - urotronic

STREAM- Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Click Here to see the Optilume Drug Coated Balloon Video

This is a single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age

 

Urge Urinary Incontinence

A Real World Study of eCoin® for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)

Click Here to review  the eCoin Info and see Video

eCoin® is the first FDA-approved tibial stimulator device for Urge Urinary Incontinence (UUI). The coin-sized device is placed under the skin, near the ankle during a safe and minimally invasive procedure.

 

Find A Physician
Powered by Lapero